SecBot SecBot
PRESS-RELEASE ·Filed Sep 1, 2026

RARE

Ultragenyx Pharmaceutical Inc.
BULLISH
Impact 7/10
Horizonweeks Processed2mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

Focus on prescription uptake and payer coverage in the coming quarters, treatment effect durability at 96 weeks supports real-world use. Watch for any confirmatory trial updates that could convert accelerated approval to full approval, further derisking revenue.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+20
Entry
$26.53
T+0 close · Sep 1, 2026 · via day close
Latest settled
−43.35%
T+20 · $15.03 · next T+60 in 10d
Vs SPY
−43.02%
α at T+20
Latest observation
−32.97%
T+52 · FF3 residual α
  1. T+0 · Sep 2 $26.53entry
  2. T+1 · 3mo ago −44.03%α −45.07% · $14.85
  3. T+5 · 2mo ago −45.72%α −44.76% · $14.40
  4. T+20 · 7w ago −43.35%α −43.02% · $15.03
  5. T+52 · todayOpen
  6. T+60 · in 10d Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Ultragenyx announced publication of 96-week Phase 3 data for GENGLYCOS (DTX401) gene therapy in glycogen storage disease Ia, showing sustained cornstarch reduction (61% at Week 96) and maintained glycemic control. The therapy was recently FDA-approved under accelerated approval, this long-term durability data supports the approval and enhances commercial prospects in a well-defined ultra-rare patient population.

Key Facts

  • GENGLYCOS (DTX401) was recently FDA approved for GSDIa patients aged 8+ under accelerated approval.
  • Phase 3 96-week data showed 61% mean reduction in daily cornstarch intake in both original and crossover groups.
  • 33% (original) and 42% (crossover) of participants completely eliminated nighttime cornstarch dosing by Week 96.
  • 83% of DTX401-treated participants met or exceeded their own expectations for meaningful cornstarch reduction at Week 48.
  • Safety profile acceptable, most common adverse events were transient liver enzyme elevations managed with corticosteroids.
  • GSDIa affects approximately 1,500-2,500 patients in the U.S. and 6,000-8,000 worldwide in accessible geographies.

Financial Impact

GENGLYCOS targets an ultra-rare population (~1,500-2,500 U.S.) with high unmet need; revenue potential depends on pricing, but FDA approval with durability data de-risks launch. Prior median analyst revenue estimates for RARE could see upward revision.

revenuemarket cap

Risk Factors

  • Accelerated approval contingent on verification of clinical benefit in confirmatory trials.
  • Competition from other gene therapies in GSDIa (none currently approved).
  • Potential safety issues like immune-mediated hepatotoxicity requiring corticosteroid management.
  • Limited patient population caps peak revenue potential.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
88% bullish (25 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3354584

Track record

22 reports on RARE

Performance horizon

8 of 9 bullish or bearish reports moved the stock their way by T+5. Best: +48.73% at T+60 after the Apr 2, 2026 report. 9 of 9 went positive at some point.

Filters
  1. Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $16.08 Now $15.90 −1.12% settles Nov 20
  2. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $16.14 Now $15.90 −1.49% settles Nov 17
  3. Nov 3, 202613d ago 8-K Mixed 6/10 No price data
  4. Nov 3, 202613d ago Press Release Bearish 6/10 Entry $17.16 to $16.70 Now $15.90 +7.34% ▲ +2.68% +1.77% vs SPY
  5. Oct 30, 202617d ago SC 13G/A Neutral 2/10 Entry $16.10 to $15.43 Now $15.90 −1.24% ▼ −4.16% −1.46% vs SPY
  6. Oct 20, 202627d ago SC 13G Neutral 3/10 Entry $15.92 to $16.75 Now $15.90 −0.13% ▲ +5.21% +5.66% vs SPY
  7. Oct 19, 202628d ago 8-K Neutral 4/10 Entry $15.07 to $16.08 Now $15.90 +5.51% ▲ +6.70% +6.85% vs SPY
  8. Oct 14, 20264w ago 8-K Bullish 6/10 Entry $14.90 to $15.92 Now $15.90 +6.71% ▲ +6.85% +6.39% vs SPY
  9. Oct 7, 20265w ago 8-K Bullish 6/10 Entry $14.89 to $14.90 Now $15.90 +6.78% ▲ +0.07% +1.05% vs SPY
  10. Sep 17, 20268w ago Press Release Bullish 8/10 Entry $14.50 to $14.77 Now $15.90 +9.66% ▲ +1.86% +1.01% vs SPY
Showing 10 of 22

US Market Status

Market Closed · Opens in 7h 35m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 1, 2026